NCT05013840

Brief Summary

The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to healthcare providers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
91

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 4, 2021

Completed
15 days until next milestone

First Posted

Study publicly available on registry

August 19, 2021

Completed
14 days until next milestone

Study Start

First participant enrolled

September 2, 2021

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 16, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 16, 2021

Completed
Last Updated

January 11, 2022

Status Verified

January 1, 2022

Enrollment Period

14 days

First QC Date

August 4, 2021

Last Update Submit

January 10, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Physician goals, evaluated with a self-constructed question.

    Goals of physicians to treat patients with neuromodulation for pain.

    Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.

  • Physician expectations, evaluated with a self-constructed question.

    Factors that respondents expect to change according to neuromodulation for pain.

    Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.

  • Physician definition of success, evaluated with a self-constructed question.

    Physician definition of success of neuromodulation for pain.

    Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.

Study Arms (1)

Physicians using neuromodulation

Behavioral: Filling in an online survey

Interventions

Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.

Physicians using neuromodulation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain (including but not limited to anesthesiologists, neurosurgeons, nurses).The survey will be spread at the 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris from 2/9/2021 to 4/9/2021.

You may qualify if:

  • \- Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain (including but not limited to anesthesiologists, neurosurgeons, nurses).

You may not qualify if:

  • \- Not involved in management of chronic pain through neuromodulation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vrije Universiteit Brussel

Brussels, 1090, Belgium

Location

Related Publications (1)

  • Goudman L, De Smedt A, Billot M, Roulaud M, Rigoard P, Moens M. Opinions of Health Care Providers About Neuromodulation for Pain: Results of an Online Survey at the 2nd Joint Congress of the International Neuromodulation Society European Chapters. Neuromodulation. 2023 Dec;26(8):1887-1892. doi: 10.1016/j.neurom.2022.04.038. Epub 2022 May 10.

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

August 4, 2021

First Posted

August 19, 2021

Study Start

September 2, 2021

Primary Completion

September 16, 2021

Study Completion

September 16, 2021

Last Updated

January 11, 2022

Record last verified: 2022-01

Locations